GlassScriptPhysician profile
Yanny L Phillips
NPI 1073831681
$2,753.16
in general payments reported to CMS, 2019-2025
29 companies · $810 in 2025
The $810 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $409 · 2021: $445 · 2022: $57.65 · 2023: $118 · 2024: $349 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.69 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $428.12 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $266.15 | 2024-2025 | Lifevest |
| Ucb, INC. | $222.72 | 2019-2025 | Briviact, Rystiggo |
| Medtronic, INC. | $187.50 | 2025 | Interstim |
| Genentech USA, INC. | $175.14 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $145.76 | 2021-2025 | Ajovy |
| Abbvie INC. | $127.61 | 2021-2025 | |
| Boston Scientific Corporation | $123.81 | 2021 | |
| Eisai INC. | $96.98 | 2019 | |
| Sk Life Science, INC. | $89.80 | 2021 | |
| Lilly USA, LLC | $85.43 | 2019 | |
| Amgen INC. | $79.86 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $75.25 | 2024-2025 | Inbrija, Ampyra |
| Neurelis, INC. | $72.58 | 2020-2025 | Valtoco |
| Lundbeck LLC | $65.83 | 2024-2025 | Vyepti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $65.24 | 2021 | |
| Biogen, INC. | $55.51 | 2020-2025 | Tysabri, Vumerity |
| Pfizer INC. | $54.85 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $53.60 | 2021 | |
| Alexion Pharmaceuticals, INC. | $49.36 | 2019-2021 | |
| Greenwich Biosciences, INC. | $42.49 | 2020 | |
| Alnylam Pharmaceuticals INC. | $41.23 | 2024-2025 | Amvuttra |
| Genzyme Corporation | $31.14 | 2020 | |
| Argenx US, INC. | $30.53 | 2024 | Vyvgart |
| Tg Therapeutics, INC. | $24.44 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $21.77 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2024 | Xifaxan |
| Acorda Therapeutics, INC | $13.88 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanny Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.